Obama's Coming Stem-Cell Decision May Not Jump-Start Research
By Paul Basken,
Chronicle of Higher Education
| 02. 05. 2009
Eight years ago, President George W. Bush sharply limited federal support for stem-cell research. The move cost universities millions of dollars while slowing the hunt for life-saving medical advances. And it may now be only days before President Obama reverses course.
But for all the trouble the presidential restriction has caused, and for all the political trauma that may accompany a cancellation of Mr. Bush's order, both the science and the economics have evolved so far since 2001 that universities may feel affected far less by Mr. Obama's decision than they were by Mr. Bush's. Still, an obscure piece of legislation called the Dickey-Wicker Amendment may remain an obstacle no matter what the president does.
Mr. Obama's anticipated reversal of policy "won't be a boon the way some people might think," said Arnold R. Kriegstein, director of the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research at the University of California at San Francisco. "Time has moved on, and so has the field."
Stem cells are capable of growing into any type of cell of the...
Related Articles
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...
By Roni Caryn Rabin, The New York Times | 01.22.2026
The National Institutes of Health said on Thursday it is ending support for all research that makes use of human fetal tissue, eliminating funding for projects both within and outside of the agency.
A ban instituted in June 2019 by...
By David Jensen, The California Stem Cell Report | 12.11.2025
California’s stem cell and gene therapy agency today approved spending $207 million more on training and education, sidestepping the possibility of using the cash to directly support revolutionary research that has been slashed and endangered by the Trump administration.
Directors...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...